ReviewDrug design, development and therapy2016
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
Review in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03216070 (Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Who cites it
23 citing papers in PubMed.
- Recent advances in piperazine derivatives as antibacterial agents: a comprehensive review (2020-2024).Molecular diversity · 2026Review
- Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib.Case reports in hematology · 2026Article
- Current and future of targeted therapies against BCR::ABL kinases.Journal of the Egyptian National Cancer Institute · 2025Review
- Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Polymeric Amorphous Solid Dispersions of Dasatinib: Formulation and Ecotoxicological Assessment.Pharmaceutics · 2024Article
- Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.Pleura and peritoneum · 2024Article
- Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience · 2023Review
- Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies.Medical oncology (Northwood, London, England) · 2023Review
- THY1 (CD90) Maintains the Adherens Junctions in Nasopharyngeal Carcinoma via Inhibition of SRC Activation.Cancers · 2023Article
- PROTACs: Walking through hematological malignancies.Frontiers in pharmacology · 2023Review
- DRPreter: Interpretable Anticancer Drug Response Prediction Using Knowledge-Guided Graph Neural Networks and Transformer.International journal of molecular sciences · 2022Article
- Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia.Medical oncology (Northwood, London, England) · 2022Article
- The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.International journal of molecular sciences · 2021Review
- Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.Journal of cellular and molecular medicine · 2021Article
- Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477.Marine drugs · 2021Article
- Piperazine based antimicrobial polymers: a review.RSC advances · 2021Review
- A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework.Pharmaceutics · 2021Article
- Review
- Senescence in Wound Repair: Emerging Strategies to Target Chronic Healing Wounds.Frontiers in cell and developmental biology · 2020Review
- Structure and Characterization of a Covalent Inhibitor of Src Kinase.Frontiers in molecular biosciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.